Adaptimmune Therapeutics - ADAP Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $6.00
  • Forecasted Upside: 265.85%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$1.64
▼ -0.02 (-1.20%)

This chart shows the closing price for ADAP by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Adaptimmune Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ADAP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ADAP

Analyst Price Target is $6.00
▲ +265.85% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Adaptimmune Therapeutics in the last 3 months. The average price target is $6.00, with a high forecast of $10.00 and a low forecast of $3.00. The average price target represents a 265.85% upside from the last price of $1.64.

This chart shows the closing price for ADAP for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 5 polled investment analysts is to buy stock in Adaptimmune Therapeutics. This rating has held steady since December 2022, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 1 sell ratings
8/15/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 1 sell ratings
11/13/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 1 sell ratings
2/11/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 1 sell ratings
5/12/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
8/10/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
11/8/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/7/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
2/6/2023

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/5/2023EF Hutton Acquisition Co. IInitiated CoverageBuy$10.00Low
1/3/2023GuggenheimUpgradeNeutral ➝ Buy$5.00Low
11/14/2022Wells Fargo & CompanyBoost TargetEqual Weight$1.50 ➝ $3.00Low
11/9/2022MizuhoUpgradeNeutral ➝ Buy$9.00Low
10/4/2022Wells Fargo & CompanyLower TargetEqual Weight$7.00 ➝ $1.50Low
3/15/2022SVB LeerinkLower TargetMarket Perform$7.00 ➝ $3.00High
11/9/2021SVB LeerinkReiterated RatingHold$7.00High
9/22/2021Wells Fargo & CompanyBoost TargetEqual Weight$6.00 ➝ $7.00Medium
9/13/2021JonestradingReiterated RatingBuy$15.00Low
9/13/2021SVB LeerinkBoost TargetMarket Perform$6.00 ➝ $7.00High
9/9/2021MizuhoInitiated CoverageHold$9.00Low
9/7/2021SVB LeerinkBoost TargetMarket Perform$5.00 ➝ $6.00High
9/7/2021JonestradingReiterated RatingBuy$15.00High
8/10/2021SVB LeerinkLower TargetMarket Perform$6.00 ➝ $5.00High
5/28/2021BarclaysInitiated CoverageUnderweight$4.00Medium
5/23/2021SVB LeerinkReiterated RatingHoldMedium
11/5/2020SVB LeerinkLower TargetMarket Perform$10.00 ➝ $6.00Low
9/9/2020Morgan StanleyInitiated CoverageEqual Weight$42.00 ➝ $42.00Low
8/12/2020Piper SandlerInitiated CoverageOverweightMedium
8/6/2020SVB LeerinkLower TargetMarket Perform$11.00 ➝ $10.00High
6/1/2020MizuhoBoost TargetNeutral$3.00 ➝ $9.00High
5/29/2020MizuhoReiterated RatingHold$3.00High
5/14/2020SVB LeerinkReiterated RatingMarket PerformHigh
4/27/2020CitigroupLower TargetBuy$8.00 ➝ $5.00High
4/21/2020MizuhoInitiated CoverageNeutral$3.00High
11/7/2019CowenReiterated RatingBuyLow
9/30/2019CowenReiterated RatingBuyHigh
8/1/2019GuggenheimDowngradeBuy ➝ NeutralHigh
5/31/2019Roth CapitalInitiated CoverageBuy$7.00Medium
5/30/2019CitigroupReiterated RatingBuy$8.00Medium
5/7/2019Raymond JamesLower TargetOutperform$16.00 ➝ $6.00Low
5/7/2019SVB LeerinkDowngradeOutperform ➝ Market Perform$4.15High
12/13/2018SunTrust BanksLower TargetBuy$12.00Medium
11/6/2018CowenReiterated RatingBuyMedium
10/22/2018Raymond JamesLower TargetOutperform ➝ Buy$20.00 ➝ $16.00High
9/17/2018GuggenheimInitiated CoverageBuyHigh
8/15/2018CowenReiterated RatingBuyLow
8/2/2018CowenReiterated RatingBuyLow
7/18/2018CowenReiterated RatingBuyLow
6/4/2018SVB LeerinkBoost TargetOutperform$20.00High
5/10/2018SunTrust BanksBoost TargetBuy$18.00High
5/9/2018CowenReiterated RatingBuyHigh
5/9/2018Raymond JamesSet TargetBuy$20.00High
4/22/2018Raymond JamesReiterated RatingBuy$20.00Low
3/16/2018SVB LeerinkInitiated CoverageBuy$15.00Low
3/15/2018SVB LeerinkReiterated RatingOutperformHigh
(Data available from 2/7/2018 forward)

News Sentiment Rating

0.80 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/11/2022
  • 1 very positive mentions
  • 4 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
8/10/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
9/9/2022
  • 1 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
10/9/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/8/2022
  • 5 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
12/8/2022
  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/7/2023
  • 3 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/6/2023

Current Sentiment

  • 3 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Adaptimmune Therapeutics logo
Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.
Read More

Today's Range

Now: $1.64
Low: $1.63
High: $1.74

50 Day Range

MA: $1.69
Low: $1.25
High: $2.19

52 Week Range

Now: $1.64
Low: $1.01
High: $3.32

Volume

135,580 shs

Average Volume

378,374 shs

Market Capitalization

$268.68 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.23

Frequently Asked Questions

What sell-side analysts currently cover shares of Adaptimmune Therapeutics?

The following sell-side analysts have issued reports on Adaptimmune Therapeutics in the last twelve months: EF Hutton Acquisition Co. I, Guggenheim, Mizuho, StockNews.com, SVB Leerink LLC, and Wells Fargo & Company.
View the latest analyst ratings for ADAP.

What is the current price target for Adaptimmune Therapeutics?

5 Wall Street analysts have set twelve-month price targets for Adaptimmune Therapeutics in the last year. Their average twelve-month price target is $6.00, suggesting a possible upside of 265.9%. EF Hutton Acquisition Co. I has the highest price target set, predicting ADAP will reach $10.00 in the next twelve months. Wells Fargo & Company has the lowest price target set, forecasting a price of $3.00 for Adaptimmune Therapeutics in the next year.
View the latest price targets for ADAP.

What is the current consensus analyst rating for Adaptimmune Therapeutics?

Adaptimmune Therapeutics currently has 2 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ADAP will outperform the market and that investors should add to their positions of Adaptimmune Therapeutics.
View the latest ratings for ADAP.

What other companies compete with Adaptimmune Therapeutics?

Other companies that are similar to Adaptimmune Therapeutics include Ocugen, VectivBio, Innate Pharma, Humacyte and Gritstone bio. Learn More about companies similar to Adaptimmune Therapeutics.

How do I contact Adaptimmune Therapeutics' investor relations team?

Adaptimmune Therapeutics' physical mailing address is 60 JUBILEE AVENUE MILTON PARK OXFORDSHIRE, ABINGDON X0, OX14 4RX. The biotechnology company's listed phone number is 441235430000 and its investor relations email address is [email protected] The official website for Adaptimmune Therapeutics is www.adaptimmune.com. Learn More about contacing Adaptimmune Therapeutics investor relations.